News & Events
Friday April 03, 2020
SAN DIEGO , April 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update regarding the company's business operations during the COVID-19 pandemic as part of its commitment to prioritize the safety, health and well-being of patients, their caregivers,
Thursday March 19, 2020
As we continue to monitor COVID-19 developments, at Neurocrine Biosciences we are committed to the safety, health and well-being of our patients, customers and employees. To healthcare providers and their patients with tardive dyskinesia, we do not anticipate any disruption in our ability to supply
Tuesday February 25, 2020
Live Audio Webcast will be on March 3, 2020 SAN DIEGO , Feb. 25, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 40 th Annual Health Care Conference at 12:00 p.m. Eastern Time on Tuesday, Mar. 3, 2020 , in Boston .
Tuesday February 04, 2020
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $238 Million with Approximately 42,100 TRx INGREZZA® (valbenazine) Full-Year 2019 Net Product Sales of $753 Million with Approximately 132,700 TRx SAN DIEGO , Feb. 4, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.
Monday February 03, 2020
SAN DIEGO , Feb. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the appointment of Shalini Sharp to its Board of Directors. Ms. Sharp is the Chief Financial Officer and Executive Vice President of Ultragenyx, a clinical-stage biopharmaceutical company focused on
Wednesday March 13, 2019
Tuesday March 12, 2019
Tuesday February 05, 2019
Tuesday January 29, 2019